Evolent Q3 2026 Earnings: Revenue Growth Comes with Margin Compression

Evolent Health (NYSE: EVH) reported Q3 2026 revenue of $725.4 million, up approximately 51.3% from $479.5 million a year earlier, while GAAP diluted loss per share improved to $0.21 from $0.24. Performance Suite expansion drove the revenue increase, but higher medical costs contributed to lower gross profit and a decline in adjusted EBITDA margin to 4.7%. The quarter covered the three months ended September 30, 2026.

Core Earnings Data

Revenue growth was concentrated in Performance Suite, while cost of revenue increased approximately 67.7%, faster than the top line. As a result, calculated gross profit declined and adjusted EBITDA fell despite lower selling, general and administrative expenses.

The GAAP net loss attributable to common shareholders narrowed, but that comparison benefited from the absence of $6.1 million in preferred dividends and accretion recorded in Q3 2025. Before preferred dividends and accretion, the loss widened to $23.6 million from $20.9 million, and operating results moved from a small profit to a loss.

Gross profit and gross margin are calculated from reported revenue less cost of revenue.

Business and Operating Performance

Performance Suite revenue nearly doubled and accounted for most of Evolent’s growth. Its average lives on platform increased approximately 11.1%, while the average per-member-per-month fee rose approximately 77.0%. Revenue declined in Specialty Technology and Services, Administrative Services and case-based programs.

Membership measures are not additive because customers covered by multiple solutions can appear in more than one category.

Evolent also announced one renewal and two new revenue agreements, bringing the year-to-date total to seven. The company renewed its largest Surgical Management customer for four years, secured an oncology expansion covering approximately 1 million commercial lives with a January 1, 2027 launch, and expanded oncology services for a national payer across 11 additional states.

Performance Suite Growth Did Not Translate into Margin Expansion

Performance Suite generated $564.3 million of revenue, but claims incurred for specialty care management reached $525.0 million. That produced a medical expense ratio of 93.0%, compared with a reported 85.0% in Q3 2025.

The reported comparison requires context because the prior-year period included Evolent Care Partners, which was sold in December 2025. Excluding that business, Q3 2025’s medical expense ratio was 91.9%, making the more comparable increase approximately 1.1 percentage points rather than the eight-point change in the reported figures.

Higher medical costs nevertheless limited profit conversion. Cost of revenue increased to $636.9 million from $379.8 million, while calculated gross margin contracted to approximately 12.2%. GAAP SG&A declined to $73.1 million from $77.6 million, and adjusted SG&A fell to $56.0 million from $62.1 million, but those savings were not enough to offset pressure in service delivery and claims costs.

Cash Flow and Balance Sheet

Evolent generated $16.1 million of operating cash flow during the first nine months of 2026, compared with a $10.0 million use of cash in the prior-year period. Cash conversion was affected by opposing working-capital movements: accounts receivable consumed $132.9 million, while the reserve for claims and performance-based arrangements provided $183.9 million.

At September 30, cash and cash equivalents totaled $148.3 million, while long-term debt, net, was $969.5 million. Accounts receivable increased to $442.8 million from $309.9 million at the end of 2025, and the claims reserve rose to $376.1 million from $192.2 million. These changes make collections and the timing of claims payments important to future cash generation.

2026 Guidance

Evolent reiterated its full-year revenue range and raised adjusted EBITDA guidance after incorporating year-to-date results. The release did not specify the previous adjusted EBITDA range, so the size of the increase cannot be quantified from the supplied information.

Management’s View

CEO Seth Blackley attributed demand to health plans seeking to control costs while maintaining patient and physician experience. Management pointed to customer renewals, expansions and execution of 2026 oncology launches as growth drivers, and expects its oncology offering and AI platform to support future growth and margin expansion.

Recent Insider Transactions

The supplied insider data shows 1,190,396 shares acquired through 13 transactions over the previous six months and one sale of 65,892 shares, producing a net increase of 1,124,504 shares. The recent acquisitions were reported as stock awards rather than open-market purchases, so they should be distinguished from cash buying by insiders.

A reported grant value of $0 does not mean the awarded shares had no economic value; it reflects the transaction classification in the supplied data. The transactions alone do not establish insiders’ views of Evolent’s prospects.

Risks Investors Should Monitor

• Medical-cost pressure: A 93.0% medical expense ratio left limited room for Performance Suite revenue to contribute to consolidated margins. Further increases could continue to pressure gross profit and adjusted EBITDA.
• Uneven business mix: Overall growth depended heavily on Performance Suite, while the other three reported revenue categories declined. Continued weakness outside Performance Suite would make results more dependent on one operating model.
• Cash-flow timing: Nine-month operating cash flow benefited from a substantial increase in claims reserves, while higher receivables consumed cash. Collections and claims-payment timing could cause cash flow to differ from earnings.
• Debt and interest burden: Evolent carried $969.5 million of long-term debt, net, and recorded $17.0 million of quarterly interest expense, limiting financial flexibility while the company remains GAAP-loss-making.
• Launch execution: The planned January 2027 oncology expansion and other newly signed agreements must be implemented effectively for contract growth to support management’s margin-expansion objective.

Conclusion

Evolent’s Q3 2026 results showed rapid Performance Suite expansion and continued customer contract activity, but revenue growth did not translate into higher adjusted EBITDA. Medical costs, a narrower gross margin and reliance on working-capital movements for cash generation remain the principal issues to monitor, alongside execution of new oncology launches and progress toward the raised full-year adjusted EBITDA range.